{
  "retracted": false,
  "timestamp": 1519344000000,
  "updates": [
    {
      "timestamp": 1585527077760,
      "identifier": {
        "doi": "10.1007/s00277-018-3277-x"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s00277-018-3229-5"
  },
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: A phase Iâ€“II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia"
}
